Current | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000

Celera Genomics and Applied Biosystems Groups Announce Computational Infrastructure Upgrade
Therapeutics Focus, New Online Applications Call for Broader Range of Technological Capabilities

Rockville, MD and Foster City, CA - September 26, 2002

Celera Genomics Group (NYSE:CRA) and Applied Biosystems Group (NYSE:ABI), Applera Corporation businesses, today announced that they will replace and upgrade the computational infrastructure supporting Celera’s drug discovery and development efforts and the Knowledge Business of Applied Biosystems.

IBM (NYSE: IBM) will provide the computational capacity server hardware, operating system and conversion services for the effort. EMC Corporation (NYSE: EMC) will supply the automated networked storage systems and software, as well as data migration services. Celera and Applied Biosystems selected IBM and EMC as the “vendors of choice,” balancing the performance, stability, flexibility and service needed to build one of the world’s largest industrial high-performance computing centers. All computational infrastructure replacements and upgrades will be implemented at the Rockville, Maryland, site. Financial terms were not disclosed.

“After carefully assessing the future computing needs of these businesses, we completed a thorough analysis of the computing technologies and players - and these companies offered the right solutions to move forward through the next phase of Celera’s drug discovery efforts and the Applied Biosystems’ service and product offerings,” said Tama Olver, Vice President and Chief Information Officer, Applera Corporation.

Building upon its ground-breaking heritage in applying large-scale computing to challenging life sciences problems, Celera will combine the next-generation computational and information storage technologies for better access to and management of its proteomics, genomics, bioinformatics and medicinal chemistry platforms to accelerate the drug discovery process.

“Celera’s goal is to maintain cutting-edge computing capabilities with a platform that has the flexibility and capacity for a wide range of discovery and development activities. Together, the technologies and services to be provided by IBM and EMC will support our dynamic scientific environment,” said Robert Booth, Senior Vice President, Research & Development, Celera Genomics.

Applied Biosystems plans to create a common platform between the Celera Discovery System (CDS), its life sciences e-commerce applications, and other products and services based on the IBM and EMC solutions. Ultimately, the expanded e-commerce portal to be developed by Applied Biosystems may be used by scientists to apply the genomic information within CDS more intelligently to their biological experiments.

“Applied Biosystems’ CDS offerings, genomic assays and other products and services will be served by the new computational infrastructure in Rockville,” said Applied Biosystems’ Deborah Smeltzer, Vice President of the Knowledge Business. “It offers the latest in current, mainstream technology and at an excellent value.”

About Applera Corporation
Applera Corporation comprises two operating groups. The Celera Genomics Group, located in Rockville, MD, and South San Francisco, CA, is engaged principally in integrating advanced technologies to discover and develop new therapeutics. Celera intends to leverage its proteomics, bioinformatics, and genomics capabilities to identify and validate drug targets and diagnostic marker candidates, and to discover and develop novel therapeutic candidates. Its Celera Discovery SystemTM online platform, marketed exclusively through the Knowledge Business of Applied Biosystems, is an integrated source of information based on the human genome and other biological and medical sources. The Applied Biosystems Group develops and markets instrument-based systems, reagents, software, and contract services to the life science industry and research community. Applied Biosystems is headquartered in Foster City, CA, and reported sales of $1.6 billion during fiscal 2002. Celera Diagnostics, a 50/50 joint venture between Applied Biosystems and Celera Genomics, is focused on discovery, development, and commercialization of novel diagnostic products. Information about Applera Corporation, including reports and other information filed by the company with the Securities and Exchange Commission, is available at, or by telephoning 800.762.6923.

Notice To Readers: Celera's press releases, presentations and printed remarks are included on this website for historical purposes only. The information contained in these documents should be considered accurate only as of the date of the relevant document. This information may change over time, and therefore visitors to this website should not assume that the information contained in these documents remains accurate at a later time. We do not have any current intention to update any of the information in these documents.